ATG16L1 and inflammatory bowel disease: In an anti‐TNF‐α treatments study in which 570 IBD patients were retrieved and analysed, patients with ATG16L1 rs10210302 were specifically significantly more prone to use adalimumab (an anti‐TNF‐α medicine).107